16.66 USD
↗ 0.01 (0.06%)AT CLOSE (03:59 PM EST)
Xeris Biopharma Holdings, Inc. Common Stock
XERSNASDAQ • USD
16.57
↘ 0.09 (0.54%)
POST MARKET (AS OF 04:15 PM EST)
Post Market
AS OF 04:15 PM EST
16.57
↘ 0.09 (0.54%)
Market: CLOSED
Xeris Biopharma Holdings, Inc. Common Stock (XERS) trades at $16.66 per share. Technical and fundamental signals align bullish — technicals rate "Strong Buy" while fundamentals indicate "Buy". This is driven by a robust Altman Z-Score, negative Return on Equity, a bullish Golden Cross on the moving averages and bullish moving average alignment. On the valuation front, XERS trades at elevated multiples relative to its peers, earning a "Richly Valued" assessment.
Technical & fundamental data as of Nov 13, 2026.
Open?$16.60
High?$16.76
Low?$16.31
Prev. Close?$16.65
Volume?3.4M
Avg. Volume?3.1M
VWAP?$16.62
Rel. Volume?1.09x
Bid / Ask
Bid?$16.47 × 100
Ask?$16.67 × 3.1K
Spread?$0.20
Midpoint?$16.57
Valuation & Ratios
Market Cap?3.0B
Shares Out?182.7M
Float?176.1M
Float %?96.6%
P/E Ratio?N/A
P/B Ratio?62.39
EPS?-$0.04
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
Employees
435
Market Cap
3.0B
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2018-06-21
Address
1375 WEST FULTON STREET, SUITE 1300
CHICAGO, IL 60607
Phone: 844-445-5704
CHICAGO, IL 60607
Phone: 844-445-5704
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+2/3)
Medium-Term (Wave)?▲ Bullish(+2/3)
Short-Term (Ripple)?– Neutral(0/3)
MA Alignment?Golden Alignment
Full Technical Analysis →Fundamental OutlookBuy
Strong SellNeutralStrong Buy
F-Score?77
Z-Score?94
Momentum?69
Short Sent.?64
Piotroski F-Score?6/9Mixed
Altman Z-Score?4.27Safe
Confidence?74%Moderate
Short InterestElevated
Short % of Float?5.10%Elevated
Short Interest?9.0M
Days to Cover?4.3
Free Float176.1M
Avg Daily Volume2.1M
Settlement Date2026-10-30
Financial Health
Current Ratio?2.15Strong
Quick Ratio?1.58Adequate
Cash Ratio?0.97Adequate
Debt/Equity?3.89High
ValuationRICHLY VALUEDvs 1 peers + S&P 500
Score33/100
P/E?N/A▾
P/B?62.39HIGH▾
Peers100
S&P3
P/S?8.27HIGH▾
Peers100
S&P12
P/FCF?41.9PRICEY▾
Peers100
S&P16
EV/EBITDA?52.6HIGH▾
Peers100
S&P3
EV/Sales?8.42HIGH▾
Peers100
S&P15
Returns & Efficiency
ROE?-13.3%WEAK▾
S&P9
ROA?-1.5%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$72.6M
Enterprise Value?$3.1B
Fundamentals ratios updated end of day